The integration of new dosage forms into the treatment of vascular cognitive impairment
https://doi.org/10.14412/2074-2711-2026-3-85-92
Abstract
This article reviews current approaches to the diagnosis and treatment of vascular cognitive impairment (VCI). It outlines the key provisions of the updated diagnostic criteria for vascular cognitive impairment from the international VasCog-2-WSO society (2025) and the STRIVE-2 neuroradiological classification of cerebral small vessel disease (2023). A clinical case report is presented of a 63-yearold female patient with mild VCI against a background of arterial hypertension, type 2 diabetes mellitus and obesity, in whom brain MRI revealed multiple lacunar infarcts and leukoaraiosis. The prescription of ethylmethylhydroxypyridine succinate in a new prolonged-release form (Armadin Long) is justified. The drug’s multimodal mechanism of action (antioxidant, antihypoxic, neuroprotective) corresponds to the key pathogenetic mechanisms of VCI, which justifies the choice of this drug for long-term treatment of cognitive disorders.
Keywords
chronic cerebrovascular disorder,
cerebrovascular insufficiency,
vascular cognitive impairment,
neuroprotective therapy
Supporting agencies: The article is sponsored by Gedeon Richter.
About the Authors
V. V. Zakharov
Department of Nervous Diseases, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Vladimir Vladimirovich Zakharov
11, Rossolimo St., Build. 1, Moscow 119021
Competing Interests:
The conflict of interests did not affect the results of the study.
O. O. Martynova
Clinical Hospital № 85 of the Federal Medical Biological Agency
Russian Federation
Competing Interests:
Russian Federation
16, Moskvorechye St., Moscow, 115409
Competing Interests:
The conflict of interests did not affect the results of the study.
References
1. Rizzi L, Rosset I, Roriz-Cruz M. Global epidemiology of dementia: Alzheimer‘s and vascular types. Biomed Res Int. 2014;2014:908915. doi: 10.1155/2014/908915
2. Sachdev PS, Bentvelzen AC, Kochan NA, et al.; VasCog-2-WSO Criteria Consortium. Revised diagnostic criteria for vascular cognitive impairment and dementia – the VasCog-2- WSO criteria. JAMA Neurol. 2025;82(11):1103- 12. doi: 10.1001/jamaneurol.2025.3242
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013. 947 p.
4. Reitan RM. Validity of the Trail Making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271-6. doi: 10.2466/pms.1958.8.3.271
5. Kiely KM, Butterworth P, Watson N, Wooden M. The Symbol Digit Modalities Test: normative data from a large nationally representative sample of Australians. Arch Clin Neuropsychol. 2014;29(8):767-75. doi: 10.1093/arclin/acu055
6. Cristofori I, Cohen-Zimerman S, Grafman J. Executive functions. Handb Clin Neurol. 2019;163:197-219. doi: 10.1016/B978-0-12-804281-6.00011-2
7. Zakharov VV, editor. Behavioral neurology. St. Petersburg: Skifiya-print; Moscow: Profmedpress; 2022. 320 p. (In Russ.).
8. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55(11):1621-6. doi: 10.1212/wnl.55.11.1621
9. Khomskaya ED. Neuropsychology. St. Petersburg: Piter; 2005. 496 p. (In Russ.).
10. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643- 62. doi: 10.1037/h0054651
11. Zakharov VV, Voznesenskaya TG. Neuropsychiatric disorders: diagnostic tests. Moscow: MEDpress-inform; 2013. 320 p. (In Russ.).
12. Gainotti G, Trojano L. Constructional apraxia. Handb Clin Neurol. 2018;151:331-48. doi: 10.1016/B978-0-444-63622-5.00016-4
13. Fedotova SL, Bykov YuN. Clinical and diagnostic characteristics of vascular parkinsonism. Sibirskiy meditsinskiy zhurnal. 2014;(1):24-7 (In Russ.).
14. Voznesenskaya TG. Depression in cerebrovascular diseases. Medical Council. 2012;(4):12-5 (In Russ.).
15. Alexopoulos GS, Meyers BS, Young RC, et al. “Vascular depression” hypothesis. Arch Gen Psychiatry. 1997 Oct;54(10):915-22. doi: 10.1001/archpsyc.1997.01830220033006
16. Bogolepova AN. Vascular depression and cognitive dysfunction. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(S3):26-31 (In Russ.). doi: 10.14412/2074-2711-2019-3S-26-31
17. Levin OS. Depression and dementia in elderly patients. Sovremennaya terapiya i psikhiatriya v nevrologii. 2012;(4):39-44 (In Russ.).
18. Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease – advances since 2013. Lancet Neurol. 2023;22(7):602-18. doi: 10.1016/S1474-4422(23)00131-X
19. Gore M, Bansal K, Khan Suheb MZ, et al. Lacunar stroke. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. PMID: 33085363.
20. Fanning JP, Wesley AJ, Wong AA, Fraser JF. Emerging spectra of silent brain infarction. Stroke. 2014;45(11):3461-71. doi: 10.1161/STROKEAHA.114.005919
21. Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology. 1965;15:774-84. doi: 10.1212/wnl.50.4.841-a
22. Yaghi S, Raz E, Yang D, et al. Lacunar stroke: mechanisms and therapeutic implications. J Neurol Neurosurg Psychiatry. 2021;92(8):823-30. doi: 10.1136/jnnp-2021-326308
23. Carey CL, Kramer JH, Josephson SA, et al. Subcortical lacunes are associated with executive dysfunction in cognitively normal elderly. Stroke. 2008;39(2):397-402. doi: 10.1161/STROKEAHA.107.500785
24. Sole-Guardia G, Tuladhar AM, de Leeuw FE. Cortical cerebral microinfarcts spark cognitive decline. Brain. 2025;148(11):3789- 91. doi: 10.1093/brain/awaf377
25. Li Q, Yang Y, Reis C, et al. Cerebral small vessel disease. Cell Transplant. 2018;27(12):1711-22. doi: 10.1177/0963689718795148
26. Das AS, Regenhardt RW, Vernooij MW, et al. Asymptomatic cerebral small vessel disease: insights from population-based studies. J Stroke. 2019;21(2):121-38. doi: 10.5853/jos.2018.03608
27. Levin OS. White matter pathology in dyscirculatory encephalopathy: diagnostic and therapeutic aspects. Trudnyy patsient. 2011;(12):16- 23 (In Russ.).
28. Sudo FK, Amado P, Alves GS, et al. A continuum of executive function deficits in early subcortical vascular cognitive impairment: a systematic review and meta-analysis. Dement Neuropsychol. 2017;11(4):371-80. doi: 10.1590/1980-57642016dn11-040007
29. Pasi M, Charidimou A, Boulouis G, et al. Mixed-location cerebral hemorrhage/microbleeds: underlying microangiopathy and recurrence risk. Neurology. 2018;90(2):e119-e126. doi: 10.1212/WNL.0000000000004797
30. Cui Y, Zhao T, Zhang W, et al. Risk factor analysis in patients exhibiting cerebral microbleeds and the correlation with cognitive impairment. J Gerontol Geriatr Med. 2024;10(2):23337214241278497. doi: 10.1177/23337214241278497
31. Hoskin J, Al Azzawi H, Huynh C, et al. Superficial siderosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 35015416.
32. Doubal FN, MacLullich AM, Ferguson KJ, et al. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke. 2010;41(3):450-4. doi: 10.1161/STROKEAHA.109.564914
33. Hernandez Mdel C, Piper RJ, Wang X, et al. Towards the automatic computational assessment of enlarged perivascular spaces on brain magnetic resonance images: a systematic review. J Magn Reson Imaging. 2013;38(4):774- 85. doi: 10.1002/jmri.24047
34. Ministry of Health of the Russian Federation. Cognitive disorders in elderly and senile persons: clinical guidelines. Moscow: Ministry of Health of the Russian Federation; 2020. 149 p. (In Russ.).
35. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment – a critical update. Front Aging Neurosci. 2013;5:17. doi: 10.3389/fnagi.2013.00017
36. Luca M, Luca A, Calandra C. The role of oxidative damage in the pathogenesis and progression of Alzheimer‘s disease and vascular dementia. Oxid Med Cell Longev. 2015;2015:504678. doi: 10.1155/2015/504678
37. Shishkova VN, Prikhodko VA, Okovityi SV. The choice of a modern neuroprotective drug as a basic strategy in the treatment of chronic cerebrovascular diseases. Medical Council. 2023;17(10):41-9 (In Russ.). doi: 10.21518/ms2023-232
38. Ostroumova OD, Plotnikova NA, Kochetkov AI, et al. Ethylmethylhydroxypyridine succinate and evidence-based neuroprotection: trends and perspectives. Meditsinskiy alfavit. 2025;(36):7-13 (In Russ.). doi: 10.33667/2078-5631-2025-36-7-13
Review
For citations:
Zakharov VV, Martynova OO. The integration of new dosage forms into the treatment of vascular cognitive impairment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2026;18(3):85-92. (In Russ.) https://doi.org/10.14412/2074-2711-2026-3-85-92
Views:
194
JATS XML
Email this article 